Deep Science Ventures

Deep Science Ventures
Name	Deep Science Ventures
Type	Venture studio; research organisation
Founded	2016
Founders	Rahul Sarpeshkar; Oscar Sharp
Headquarters	London, United Kingdom
Key people	Rahul Sarpeshkar; Oscar Sharp; Christopher Bishop; Demis Hassabis
Industry	Deep technology; biotechnology; climate technology; materials science

Deep Science Ventures

Deep Science Ventures is a London-based research-led venture studio that builds and funds companies by combining scientific research with entrepreneurship. It operates at the intersection of laboratory research, startup formation, and capital allocation, engaging with academic institutions, industrial partners, and investors to create ventures across life sciences, energy, and materials. The organisation has been associated in public discourse with innovators and institutions active in artificial intelligence, synthetic biology, and climate technology.

History

Founded in 2016, the organisation emerged amid increasing activity in deep technology incubation across London and global innovation hubs, paralleling initiatives at Imperial College London, University College London, and Cambridge University. Early collaborators and advisors included figures from DeepMind, Microsoft Research, and Alphabet Inc. affiliates; contemporaneous ecosystem actors included Entrepreneur First, Y Combinator, and Index Ventures. The studio’s formation occurred alongside policy and funding moves by Innovate UK, European Investment Fund, and philanthropic efforts from organisations like the Wellcome Trust and Bill & Melinda Gates Foundation. Throughout its history, the studio engaged with researchers who previously worked at Harvard University, Massachusetts Institute of Technology, Stanford University, and ETH Zurich.

Mission and Approach

The stated mission emphasizes creating companies that address scientifically hard problems by combining research, engineering, and venture creation. The approach borrows elements from design thinking used at IDEO, systems engineering practised at NASA, and translational pathways championed by National Institutes of Health and US Department of Energy laboratories. The studio uses hypothesis-driven R&D workflows similar to methods adopted at Google X and operational playbooks influenced by McKinsey & Company and BCG Digital Ventures. It develops IP portfolios akin to technology transfer processes found at Oxford University Innovation and Cambridge Enterprise while aligning with investment frameworks used by Sequoia Capital and Atomico.

Investment Model and Ventures

The organisation employs a venture-studio model distinct from traditional accelerators like Techstars and 500 Startups, and from corporate venture arms such as GV and Intel Capital. It sources problems through partnerships with entities including Royal Society fellows, labs at Francis Crick Institute, and industry consortia formed with BP and Shell-adjacent research programmes. Capitalization strategies reference structures used by SoftBank Vision Fund and Andreessen Horowitz while also engaging public and philanthropic funding channels used by Horizon 2020 and European Commission grants. Portfolio companies are typically spun out as independent entities, following legal and corporate practices similar to those of Cambridge Innovation Capital and Imperial Innovations.

Notable Companies and Projects

Projects span synthetic biology, energy storage, materials, and industrial decarbonisation. Some ventures have thematic similarity to startups such as Zymergen, Ginkgo Bioworks, Ceres Power, and Oxford PV; collaborations and competitive spaces include Carbon Engineering, Climeworks, Storegga, and Octopus Energy. Research outputs align with laboratory infrastructures comparable to Diamond Light Source and Max Planck Institutes groups. The studio’s ventures have engaged with regulatory pathways akin to those navigated by European Medicines Agency, Food and Drug Administration, and certification regimes linked to UK Research and Innovation. Strategic partnerships have involved industry actors comparable to Unilever, BP Ventures, and Schneider Electric.

Organizational Structure and Leadership

Leadership has blended scientists, entrepreneurs, and investors, drawing advisory participation from personalities and institutions such as Demis Hassabis, Christopher Bishop, and researchers associated with Wellcome Sanger Institute. Operational teams often include alumni of McKinsey & Company, Goldman Sachs, and programme managers experienced with Nesta and Royal Academy of Engineering fellowships. Governance models reflect best practices from corporate structures adopted at Publicis Groupe and university spinout offices such as Oxford University Innovation. Board and advisory members have historically included academics from Imperial College London, researchers affiliated with John Innes Centre, and investors with track records at Index Ventures and Accel Partners.

Impact and Criticism

Advocates cite the studio’s role in accelerating deep-technology translation, comparing its model to success stories at Bell Labs and Salk Institute-adjacent spinouts. Critics raise questions common to venture studios and lab-to-market efforts, referencing debates involving Theranos, BioNTech’s rapid translation, and scrutiny experienced by platform-oriented companies like Zymergen. Concerns often address capital intensity, timelines similar to those for projects at CERN and Joule Unlimited, and technology readiness challenges seen in fusion initiatives linked to firms like Commonwealth Fusion Systems and Tokamak Energy. Policy commentators have contrasted the studio’s model with public research funding norms at UK Research and Innovation and philanthropic approaches exemplified by Howard Hughes Medical Institute.

Category:Venture studios Category:Biotechnology companies of the United Kingdom